Microbial infection is a key health management issue for peritoneal dialysis (PD) patients.
One of the most attractive benefits of peritoneal dialysis (PD) to patients with impaired kidney function is the freedom to independently perform treatment at home, whilst travelling and/or at work. It is often the preferred therapy for patients as it is considered the least compromising in terms of impact on lifestyle. However microbial infection is a key health management issue for patients.
The average duration of PD therapy is limited 2 to 5-years, due largely to the impact of recurrent infections, which are the major cause of failure for this treatment modality. Recurrent infection compromises the ability of the peritoneum to effectively transfer fluids and consequently patients will move onto the more restrictive haemodialysis (HD) treatment form.
It is our goal to extend the average duration of PD therapy by improving current infection management and control, thereby increasing the market share of PD over the medium term.